Neuroimaging, Urinary, and Plasma Biomarkers of Treatment Response in Huntington’s Disease: Preclinical Evidence with the p75(NTR) Ligand LM11A-31

Huntington’s disease (HD) is caused by an expansion of the CAG repeat in the huntingtin gene leading to preferential neurodegeneration of the striatum. Disease-modifying treatments are not yet available to HD patients and their development would be facilitated by translatable pharmacodynamic biomark...

Descripción completa

Detalles Bibliográficos
Autores principales: Simmons, Danielle A., Mills, Brian D., Butler III, Robert R., Kuan, Jason, McHugh, Tyne L. M., Akers, Carolyn, Zhou, James, Syriani, Wassim, Grouban, Maged, Zeineh, Michael, Longo, Frank M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423954/
https://www.ncbi.nlm.nih.gov/pubmed/33786806
http://dx.doi.org/10.1007/s13311-021-01023-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8423954/
https://www.ncbi.nlm.nih.gov/pubmed/33786806
http://dx.doi.org/10.1007/s13311-021-01023-8

Ejemplares similares